Agios appoints Cecilia Jones as CFO effective Sept 26; replaces Jonathan Biller

AGIOS PHARMACEUTICALS, INC.

Cecilia Jones appointed CFO, effective Sept 26, 2022, replacing Jonathan Biller who resigned Sept 16 to become CLO at Vertex.
Jones previously CFO at LogicBio; 10+ years at Biogen in various finance roles including VP of R&D and BD finance.
Compensation: $475k base salary, 45% target annual bonus, $1.875M stock option, $625k RSUs, $300k PSUs.
Stock option vests: 25% on first anniversary, then monthly through year 4; RSUs vest equally over 3 years.
Company highlights PYRUKYND commercial launch and five pivotal trials; Jones to lead financial strategy.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Cecilia Jones

Chief Financial Officer

AGIO · AGIOS PHARMACEUTICALS, INC.

Effective: 2022-09-26
Filed: September 19, 2022, 7:59 PM ET

On September 15, 2022, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”) appointed Cecilia Jones as the Company’s Chief Financial Officer effective as of September 26, 2022 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Cecilia Jones was appointed as Chief Financial Officer at AGIOS PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On September 15, 2022, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”) appointed Cecilia Jones as the Company’s Chief Financial Officer effective as of September 26, 2022 (the “Effective Date”).

View on SEC.gov

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-246740

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.